参考文献/References:
[1] 徐骏, 钱伟庆, 宋建达. 比较不同剂量舍尼通在防止良性前列腺增生疾病进程中的作用[J]. 中华男科学杂志, 2008, 14(6): 533-537.
[2] Filson CP, Hollingsworth JM, Clemens JQ, et al. The efficacy and safety of combined therapy with a-blockers and anticholinergics for men with benign prostatic hyperplasia: a meta-analysis[J]. J Urol, 2013, 190(6): 2153-2160.
[3] Mochtar CA, Kiemeney LA, van Riemsdijk MM, et al. Prostate-specific antigen as an estimator of prostate volume in the management of patients with symptomatic benign prostatic hyperplasia[J]. Eur Urol, 2003, 44(6): 695-700.
[4] Park DS, Oh JJ, Hong JY, et al. Serum prostate-specific antigen as a predictor of prostate volume and lower urinary tract symptoms in a community-based cohort: a large-scale Korean screening study[J]. Asian J Androl, 2013, 15(2): 249-253.
[5] De Nunzio C, Autorino R, Bachmann A, et al. The diagnosis of benign prostatic obstruction: Development of a clinical nomogram[J]. Neurourol Urodyn, 2016, 35(2): 235-240.
[6] Coric J, Mujic J, Kucukalic E, et al. Prostate-specific antigen(PSA) and prostate volume:better predictor of prostate cancer for Bosnian and Herzegovina men[J]. Open Biochem J, 2015, 15(9): 34-36.
[7] Pejcic TP, Tulic CDz, Lalic NV, et al. Urinary prostate-specific antigen: predictor of benign prostatic hyperplasia progression[J]. Can J Urol, 2013, 20(2): 6707-6713.
[8] Schr?der FH, Hugosson J, Roobol MJ, et a1. Prostate cancer mortality at 11 years of follow-up[J]. N Engl J Med, 2012, 366(11): 981-990.
[9] Bohnen AM1, Groeneveld FP, Bosch JL. Serumprostate-specific antigen as a predictorof prostate volume in the community: the Krimpen study[J]. Eur Urol, 2007, 51(6): 1645-1652.
[10] Park DS1, Oh JJ, Hong JY , et al. Serum prostate-specific antigen as a predictor of prostate volume and lower urinary tract symptoms in a community-based cohort: a large scale Korean screening study[J]. Asian J Androl, 2013, 15(2): 249-253.
[11] Bansal A, Arora A. Predictors of successful trial without catheter following acute urinary retention in benign prostatic enlargement: A single centre, multivariate analysis[J]. Neurourol Urodyn, 2017, 36(7): 1757-1762.
[12] Yoshida T, Kinoshita H, Yoshida K , et al. Intravesical prostatic protrusion as a predicting factor for the adverse clinical outcome in patients with symptomatic benign prostatic enlargement treated with dutasteride[J]. Urology, 2016 ,91(1):154-157.
[13] Ho CC, Ngoo KS, Hamzaini AH, et al. Urinary bladder characteristics via ultrasound as predictors of acute urinary retention in men with benign prostatic hyperplasia[J]. Clin Ter, 2014, 165(2): 75-81.
相似文献/References:
[1]李辽源,高新,李解方,等.血清/尿PSA比值对血清PSA处于"灰区"中前列腺癌的诊断价值[J].中华腔镜泌尿外科杂志(电子版),2008,(03):52.
LI Liao-yuan,GAO Xin,LI Xie-fang,et al.The role of the ratio of serum PSA and urine PSA in diagnosing prostate carcinoma within the serum PSA "gray" zone[J].,2008,(03):52.
[2]赵亮,王文卫,涂响安,等.经尿道双极等离子电切治疗前列腺增生122例临床分析[J].中华腔镜泌尿外科杂志(电子版),2011,(04):286.
ZHAO Liang,WANG Wen-wei,TU Xiang-an,et al.Clinical analysis of transurethral bipolar plasma kinetic resection of the prostate for benign prostatic hyperplasia: Report of 122 cases[J].,2011,(03):286.